The importance of MDR1 gene polymorphism for the individualization of analgesic therapy in oncology
Abstract
The review focuses on the importance of glycoprotein-P for the effective and safe analgesic therapy of opioids in oncology. The importance of the effect of inter-drug interactions on glycoprotein-P activity in conditions of multicomponent palliative therapy is shown. The main substrates, inhibitors and inducers of glycoprotein-P, which have the most actual importance in clinical oncology, are presented. The role of MDR1 gene encoding for glycoprotein-P has been highlighted for the phenotypic variety of chronic pain and the profile of analgesic therapy safety. The key role for the clinical oncology and palliative medicine of the pharmacogenetic factors of the gene encoding glycoprotein-P in a personified approach to analgesic therapy is presented.
About the Authors
O. P. Bobrova
Federal State Budgetary Educational Institution of Higher Education «Prof. V.F. Voino-Yasenetsky Krasnoyarsk State Medical University» of the Ministry of Healthcare of the Russian Federation
Russian Federation
Russian Federation
N. A. Shnayder
Federal State Budgetary Educational Institution of Higher Education «Prof. V.F. Voino-Yasenetsky Krasnoyarsk State Medical University» of the Ministry of Healthcare of the Russian Federation
Russian Federation
Russian Federation
D. A. Sychev
Federal State Budgetary Educational Institution of Further Professional Education «Russian Medical Academy of Postgraduate Education» of the Ministry of Healthcare of the Russian Federation
Russian Federation
Russian Federation
M. M. Petrova
Federal State Budgetary Educational Institution of Higher Education «Prof. V.F. Voino-Yasenetsky Krasnoyarsk State Medical University» of the Ministry of Healthcare of the Russian Federation
Russian Federation
Russian Federation
References
1. Yiannakopoulou E. Pharmacogenomics and Opioid Analgesics: Clinical Implications. I nternational Journal of Genomics. 2015; 1-8. http://dx.doi. org/10.1155/2015/368979.
2. Muralidharan A., Smith M.T. Pain, analgesia and genetics. JPP.2011; 63: 1387 - 1400. doi10.1111/j.2042-7158.2011.01340.x.
3. Котловский М.Ю., Покровский A.A., Котловская О.С., ОседкоА.В., Оседко О.Я., Титова Н.М. и др. Ген SLCO1B1 в аспекте фармакогенетики. Сибирское медицинское обозрение. 2015; 1: 5-15.
4. Giacomini K.M., Huang S.M., Tweedie D.J., Benet L.Z., Brouwer K.L., Chu X. et al. Membrane transporters in drug development. Nat. Rev. Drug. Discov. 2010; 9 (3): 215-236. doi: 10.1038/nrd3028.
5. Deenen M.J., Cats A., Beijnen J.H., Schellens J.H. Pharmacogenetic variability in drug transport and phase I anticancer drug metabolism part Oncologist. 2011; 16: 820-834. doi:10.1634/theoncologist.2010-0259.
6. Brambila - Tapia A.J.L. Effect of VDR1 (ABCB1) polymorphisms. Rev Invest Clin. 2013; 65 (5): 445-454. PMID:24687344.
7. Якушева Е.Н., Черных И.В., Щулькин A.B., Попова Н.М. Гликопротеин - P: структура, физиологическая роль и молекулярные механизмы модуляции функциональной активности. Успехи физиологических наук. 2014; 45 (4): 90-98.
8. Sharom F.J. The P - glycoprotein multidrug transporter. Essays Biochem. 2011; 50: 161-78. doi: 10.1042/bse0500161.
9. Ташенова A.И. Транспортная система гликопротеина-Р и фармакокинетика лекарственных средств. Биомедицина. 2010; 4: 24-32.
10. Sia A.T., Sng B.L., Lim E.C., Law H., Tan E.C. The influence of ATP - binding cassette sub-family B member -1 (ABCB1) genetic polymorphisms on acute and chronic pain after intrathecal morphine for caesarean section: a prospective cohort study. Int J Obstet Anesth. 2010; 19: 254-260. doi: 10.1016/j.ijoa.2010.03.001.
11. Ding Z., Yang L., Xie X., Xie F., Pan F., Li J., He J., Liang H. Expression and significance of hypoxiainducible factor-1 alpha and MDR1/P-glycoprotein in human colon carcinoma tissue and cells. Cancer Res Clin Oncol. 2010; 3:1276-1282. doi: 10.1007/s00432-010-0828-5.
12. Cetinkalp S., Karadeniz M., Erdogan M., Ero lu Z., Zengi A., Kosova B. et al. Human multidrug resistance-1 gene expression levels in graves-basedow disease. Exp. Clin. Endocrinol. Diabetes. 2010; 118 (3): 158-160. doi: 10.1055/s-0029-1215586.
13. Marz.olini C., Paus E., Buclin T., Kim R.B. Polymorphisms in human MDR1 (P-glycoprotein): Recent advances and clinical relevance. Clin Pharmacol Ther. 2004; 75 (1): 13-33. doi: 10.1016/j.clpt.2003.09.012.
14. Krishnamurthy S., Tichenor M.D., SatishA. G., Lehmann D.B. A proposed role for efflux transporters in the pathogenesis of hydrocephalus. Croat Med. J. 2014; 55 (4): 366-376. doi: 10.3325/cmj.2014.55.366.
15. Якушева Е.Н. и др. Половые различия функциональной активности и экспрессии гликопротеина-P у кроликов. Российский физиологический журнал им. И.М. Сеченова. 2014; 100 (8): 944-952.
16. Якушева Е.Н., Черных И.В. Влияние экспериментальной подострой гипобарической гипоксической гипоксии на функциональную активность гликопротеина-P. Рос. медико-биол.вестн. им. акад. И.П. Павлова. 2013; 1: 60-64.
17. Thews O., Dillenburg W., Fellner M., Buchholz H.G., Bausbacher N., Schreckenberger M. et al. Activation of P-glycoprotein (Pgp)-mediated drug efflux by extracellular acidosis: in vivo imaging with 68Ga-labelled PET tracer. Eur. J. Nucl. Med. Mol. Imaging.2010; 37 (10): 1935-1942. doi: 10.1007/s00259-010-1504-3.
18. Zwisler S.T., Enggaard T.P., Noehr-Jensen L., Mikkelsen S., Verstuyft C., Becquemont L. et al. The antinociceptive effect and adverse drug reactions of oxycodone in human experimental pain in relation to genetic variations in the OPRM1 and ABCB1 genes. Fundam Clin Pharmacol. 2010; 24 (4): 517-524. doi: 10.1111/j.1472-8206.2009.00781.x.
19. Kesimci E., Engin A.B., Kanbak O., Karahalil B. Association between ABCB1 gene polymorphisms and fentanyl’s adverse effects in Turkish patients undergoing spinal anesthesia.Gene.2012; 493 (2): 273-277. doi:10.1016/j. gene.2011.11.040.
20. Shitara K., Matsuo K., Ito S., Sawaki A., Kawai H., Yokota T. et al. Effects of genetic polymorphisms in the ABCB1 gene on clinical outcomes in patients with gastric cancer treated by second-line chemotherapy. Asian Pac J Cancer Prev.2010; 11 (2): 447-452. https://www.researchgate.net/ publication/46280511.
21. Laugsand E.A., Fladvad T., Skorpen F., Maltoni M., Kaasa S., Fayers P., Klepstad P. Clinical and genetic factors associated with nausea and vomiting in cancer patients receiving opioids. Eur J Cancer. 2011; 47 (11): 1682-1691. doi: 10.1016/j.ejca.2011.04.014.
22. Rhodin A., Gr nbladh A., Ginya H., Nilsson K.W., Rosenblad A., Zhou Q. et al. Combined analysis of circulating beta-endorphin with gene polymorphisms in OPRM1, CACNAD2 and ABCB1 reveals correlation with pain, opioid sensitivity and opioid-related side effects. Mol Brain 2013; 6: doi: 10.1186/1756-6606-6-8.
23. Смирнова О.В. Половые различия действия лекарств: роль белков множественной устойчивости к лекарствам.Физиология человека. 2012; 38 (3): 124-136.
24. Sharom F.J. The P-glycoprotein multidrug transporter. Essays Biochem. 2011; 50 (1):161-78. doi: 10.1042/bse0500161.
25. Duan G., Xiang G., Zhang X., Yuan R., Zhan H., Qi D. A single - nucleotide polymorphism in SCN9A may decrease postoperative pain sensitivity in the general population. Anesthesiology. 2013; 118: 436-442. doi: 10.1097/ALN.0b013e31827dde74.
26. Trescot A.M., Faynboym S. A revie wof the role of genetic testing in pain medicine. Pain Physician. 2014; 17 (5): 425-445.PMID:25247900.
Review
For citations:
Bobrova O.P., Shnayder N.A., Sychev D.A., Petrova M.M. The importance of MDR1 gene polymorphism for the individualization of analgesic therapy in oncology. Pharmacogenetics and Pharmacogenomics. 2017;(1):25-29. (In Russ.)
Views:
633
Email this article 
Post a Comment 